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The histochemical characteristics of human basophils and tissue mast cells were described
over a century ago by Paul Ehrlich. When mast cells are activated by an allergen that binds
to serum IgE attached to their Fc 3RI receptors, they release cytokines, eicosanoids and their
secretory granules. Mast cells are now thought to exert critical proinflammatory functions,
as well as potential immunoregulatory roles, in various immune disorders through the release
of mediators such as histamine, leukotrienes, cytokines chemokines, and neutral proteases
(chymase and tryptase). The aim of this review is to describe the role of mast cells in allergic
inflammation.
Mast cells interact directly with bacteria and appear to play a vital role in host defense
against pathogens. Drugs, such as glucocorticoids, cyclosporine and cromolyn have been shown
to have inhibitory effects on mast cell degranulation and mediator release. This review shows
that mast cells play an active role in such diverse diseases as asthma, rhinitis, middle ear infec-
tion, and pulmonary fibrosis.
In conclusion, mast cells may not only contribute to the chronic airway inflammatory
response, remodeling and symptomatology, but they may also have a central role in the initi-
ation of the allergic immune response, that is providing signals inducing IgE synthesis by B-
lymphocytes and inducing Th2 lymphocyte differentiation.
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Mast cells are found in the skin and in all mucosal tissues at
homeostasis, and numbers are elevated in asthmatics lungs1
and gastrointestinal tract of inflammatory bowel disease.
Mast cells were first described by Ehrlich in his 1878 doctoral
thesis on thebasis of their unique staining characteristics and
large granules, that gave them their name, “Mastzellen”
which means well-fed cells, because their cytoplasm was
stuffedwith granularmaterial. Mast cells are nowconsidered
tobepart of the immune system.Themast cellwas identified
as a mesenchymal cell which is stained metachromatically
with someblue dyes and it was recognized several years later
that these cells contained in their granules the majority of
the body’s histamine.2 Mast cells play a central role in
inflammatory and immediate allergic reactions. They are
able to release potent inflammatory mediators, such as
histamine, proteases, chemotactic factors, cytokines and
metabolites of arachidonic acid that act on the vasculature,
smooth muscle, connective tissue, mucous glands and
inflammatory cells.3 Histamine is not only released when the
body encounters a toxic substance, it is also released when
mast cells detect injury. It causes nearby blood vessels to
dilate allowing more blood to reach the site of the injury or
infection. Mast cells are localized in the connective tissue
and do not usually circulate in the blood stream.
The aim of this review is to discuss the effects of
different Th2 cytokines on mast cell development, and the
contribution of these cells to the chronic airway inflam-
matory response, tissue remodeling and symptomatology,
and also to understand the role of these cells at the initi-
ation of the allergic immune response, where they provide
signals inducing IgE synthesis by B-lymphocytes and Th2
lymphocyte differentiation.Mast cell development and differentiation
Mast cells arise in the bone marrow where maturation is
influencedbystemcell factor binding to the receptor c-kit and
by other cytokines such as interleukin (IL)-3, IL-4, IL-9, and IL-
10. These cytokines promote differentiation and proliferation
of both human and mouse mast cells.4e7 The SCF receptor (c-
kit) plays an important role in the hematopoiesis during
embryonic development. Mast cell is the only terminally
differentiated hematopoietic cell that expresses the c-Kitreceptor. In addition, SCF promotes mast cell adhesion,
migration, proliferation, and survival.8 SCF also promotes the
release of histamine and tryptase, which are involved in the
allergic response.Mastcell progenitors leavethebonemarrow
and settle in various tissues dependent of stimulation.9 Two
types ofmast cells, mucosal and connective tissuemast cells,
were reported in rodent tissue in the 1960’s on the basis of
histochemicalandfixationcharacteristics that reflect, inpart,
whether heparin proteoglycan was present in secretory
granules. Mucosal mast cell (MMC) granules stain blue with
copper phthalocyanin dyes, such as Astra blue or Alcian blue,
in a staining sequence with safranin, while connective tissue
mast cell (MCTC) granules stain red.10MC(T) andMC(TC) types
of humanmast cells (MCs) are distinguished from one another
on the basis of the protease compositions of their secretory
granules, but their structural, functional differences and
developmental relationships have beenwell characterized by
other authors.11,12 Mast cells are long-lived, surviving for
month or even years, in the tissue. Evolutionary, mast cells
existed and participated in host defense long before the
development of cells of adaptive immune system. Increased
numbers of MCT and MCTC mast cells are seen in fibrotic
diseases whereas its numbers are relatively unchanged in
allergic or parasitic diseases and in HIV infection.13 The
presence of these MCTC cells could help explain why patients
with HIV infection continue to have allergic reactions. The
MCTC mast cell, however, expresses tryptase, chymase. It
tends to predominate in the respiratory tract, gastrointestinal
tract as well as in skin, synovium, and subcutaneous tissue.
Mast cell activation and mediator production
The cytoplasm of mast cells contains organelles: lipid bodies
where metabolism of arachidonic acid occurs and where the
products of this metabolism, including leukotrienes, are
stored.14 Cytokines and histamine are other products found
in mast cells organelles (Fig. 1). These organelles are prone
to exocytosis and extracellular release of mediators. The
release may be induced by: (a) chemical substances, such as
toxins, venoms, and proteases; (b) endogenous mediators,
including tissue proteases, cationic proteins derived from
eosinophils and neutrophils; (c) immune mechanisms that
may be IgE-dependent or IgE-independent. IgE-dependent
degranulation is a consequence of the preferential produc-
tion of IgE, in response to certain antigens (allergens). During
an allergic response IgE release from B-cells will bind tomast
Figure 1 The IgE-primed mast cell releases granules and
powerful chemical mediators, such as histamine, cytokines,
granulocyte macrophage colony-stimulating factor (GM-CSF),
leukotrienes, heparin, and many proteases into the environ-
ment. These chemical mediators cause the characteristic
symptoms of allergy.
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cells. Half a million IgE molecules coat the surface of mast
cells, binding to the high-affinity IgE receptors (Fc 3RI) on
membranes with the Fc portion. This leaves their Fab, or
antigen binding segment, free to bind the antigen.9,13,15,16 A
subsequent exposure to the same allergen cross-links the
cell-bound IgE and triggers the release of preformed pros-
taglandins, histamines and cytokines (Fig. 2).9,14,17e19 Mast
cell degranulation is preceded by increased Ca2þ influx,
which is a crucial process; ionophores that increase cyto-
plasmic Ca2þ also promote degranulation, whereas agents
which deplete cytoplasmic Ca2þ suppress degranulation
(Fig. 2).18,20 Additionally, in some cases, other
ligandereceptor interactions, summarized in Fig. 1, can lead
to mast cell degranulation.
Newly generated mediators, often absent in the resting
mast cells, are as well produced during IgE-mediated acti-
vation, and consist of arachidonic acid metabolites, prin-
cipally leukotriene C4 (LTC4), prostaglandin D2 (PGD2) and
of cytokines.21e23 Of particular interest in humans is the
production of tumor necrosis factor (TNF-a, b), and inter-
leukin (IL)-4, IL-5, IL-6, IL-1b and IL-13.9,24e26 Those lipid
mediators and cytokines and preformed histamine, can
have profound effects on vascular endothelium, including
the alteration of vascular permeability and adhesiveness.
This can allow other circulating inflammatory cells to
adhere to the endothelium and to migrate into the
surrounding tissue. Cytokines and lipid mediators do as well
elicit a direct influence on lymphocytes and macrophages in
the murine system.27 IL-4, IL-5 and IL-6 stimulates theproliferation and differentiation of activated B-cells, and
induces class switch.9,28,29 However, B-cells stimulated
with IL-5 become plasma cells secreting IgA. IL-5 is also very
important in stimulating growth and differentiation of
eosinophils.30e33 The production of cytokines by human
mast cells has not been as extensively studied as in rodents,
but several studies suggest that it has a similar pattern. For
example, human mast cells have been shown to produce IL-
4, IL-5, and IL-6.30,31 In addition, mast cells produce several
neutral proteases including tryptase and chymase that
potentially damage and activate the bronchial epithelium,
and may contribute to airway wall remodeling. Thus, mast
cells are key players in host defense, with a role in immune
surveillance, phagocytosis, and immune activation.Functions of mast cells in physiological and
pathological states
The biological function of mast cell neutral proteases
remains to be fully clarified. In serum, elevated levels of
tryptase are detected in systemic mast cell disorders, such
as anaphylaxis and mastocytosis. Ongoing mast cell activa-
tion in asthma appears to be a characteristic of the chronic
inflammatory nature of the disease. Activation is detected
by elevated levels of tryptase and PGD2 in bronchoalveolar
lavage (BAL) and higher spontaneous release of histamine by
mast cells obtained from the BAL of asthmatics than those
obtained from non asthmatics.21 Ultrastructural analysis of
mast cells in lung tissue also shows that asthmatics have
more degranulation than atopic nonasthmatics.34 The
number of the cells increases at sites of inflammation. To
reach these areas, mast cell progenitors must migrate from
the blood into tissue sites. A crucial step in this process is the
adherence of cells to the endothelium. Cell adherence is
mediated by several families of adhesion molecules and
adhesion receptors on the surface of mast cells that can
mediate binding to other cells and to extracellular matrix
(ECM) glycoprotein. Upon stimulation, mast cells release
cytokines, including TNF-a and IL-4 that can modulate
adhesion molecules on endothelial cells. Activated endo-
thelial cells express the intercellular adhesion molecule
(ICAM-1), endothelial-leukocyte adhesion molecule-1
(ELAM-1) and vascular cell adhesion molecule (VCAM-1) on
their cell surface.35,36 Human mast cells express integrins as
receptors for these molecules. Until recently, the effects of
adherence on cell function were believed to result only from
changes in cell shape and cytoskeletal organization.
However, in addition to cell spreading, aggregated adhesion
receptors transduce a variety of intracellular signals that
regulate cell function. These signals include protein tyrosine
phosphorylation, phosphoinositide hydrolysis and changes in
intracellular pH or calcium concentration and the expression
of several genes. The adhesion properties of the cells regu-
late their migration, localization, proliferation and pheno-
type. Recently, murine mast cells have been implicated in
the mediation of inflammatory responses at long distances.
TNF alpha containing particles released by the cells were
found transported through draining lymphatic system acti-
vating cells in the lymph nodes.37
Different mechanisms could contribute to the increase in
the number of mast cells at the sites of tissue injury: mast
Figure 2 Induction and effector mechanisms in type I hypersensitivity.
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resident mast cell precursors could proliferate. Adhesion
receptors and their ligands also play a role in the localization
and migration of mast cells in normal tissues. ECM proteins
that are the ligands for adhesion receptors are chemotactic
for mast cells. Adherence of mast cells to fibroblasts, other
cells or to ECM proteins can transduce signals that affect cell
growth and differentiation. The increase in the number of
mast cells,38,39 and the enhanced secretion at sites of
inflammation, can accelerate the elimination of the cause of
tissue injury or, paradoxically, may lead to a chronic
inflammatory response. Thus, manipulating mast cell adhe-
sionmay be an important strategy in controlling the outcome
of allergic and inflammatory responses.
In a previous study by us,1 Mast cell numbers were
increased in both allergic and non-allergic asthma. Similar to
amore recent study,we found17 infiltration ofmast cells in of
the bronchi of both allergic asthmatics and non-allergic
asthmatics40 but the accumulation of mast cells was more
pronounced for the allergic asthmatics. We did also find that
mast cells in the bronchial mucosa of the allergic asthmatics
showed more signs of activation with extracellular deposi-
tion of tryptase than mast cells from non-allergic asth-
matics.1 Signs of mast cell activation in allergic asthma have
been indicated by others.40 However, in that study we could
not observe any differences between allergic and non-
allergic asthmatics.40 This could be explained by limited
number of non-allergic asthmatics included in the study.
Specific allergens and their reaction with IgE on the mast
cells might provide the mechanisms for activation in thebronchial mucosa in allergic asthma, especially since all
those patients were sensitized to perennial allergens such as
from pets.41
Also, other authors found inflammatory cells in bronchial
mucosa in subjects with toluene Diisocyanate (TDI) induced
asthma.42 The mast cell, which is one of the inflammatory
cells, plays an important role in TDI activation because the
activation of mast cells is associated with TDI-induced early
and late asthmatic reaction.42,43
Mast cells are increased in number in many fibrotic
diseases and may play a crucial role in the development of
fibrosis.44,45 The percentage of humanmast cells in BAL fluid
frompatientswith sarcoidosis or interstitial fibrosis is greater
than in BAL fluid from healthy individuals,44,46 and patients
with idiopathic interstitial pulmonary fibrosis show evidence
ofmast cell degranulation and elevatedmast cell numbers.47
Concluding in a previous study show that Mast cells are
located in connective tissue, including the lung, skin, the
linings of the stomach and intestine, and other sites. They
play an important role in helping defend these tissues from
diseases. By releasing chemical such as histamine, mast
cells attract other key players of the immune defense
system to areas of the body where they are needed.Mast cells and airway remodeling
Tissue remodeling is characteristic feature of asthma and
other lung diseases. The mechanisms behind this relation-
ship between mast cells and fibrosis/tissue remodeling are
Figure 3 Staining of tissue mast cells with anti-tryptase antibody 1 (AA1) in (A) airway smooth muscle (arrow) of patients with
allergic asthma and (B) control subjects, respectively. (Mayer’s hematoxylin). Original magnification: 40. The scale bars 50 mm for
A and B are shown in the figures.
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a substantial effect on tissue remodeling, especially in the
airway, on smooth muscle hypertrophy and on mucus hyper-
secretion, by releasing proteases such as tryptase, and
growth factors.17 These cells also have an effect on
epithelial damage, and on basement membrane thickening
in patients with allergic asthma,1,48 allergic rhinitis,49 and
middle ear infection in allergy patients,50,51 mast cells
related to airway smooth muscle hypertrophy, compared to
healthy controls.17 Fig. 3 shows that mast cells specifically
are localized within or close to airway smooth muscle
bundles in patients with allergic asthma whereas little or no
mast cells are found in the airways of healthy controls
(Fig. 3). Tryptase and other proteases such as chymase are
abundant in mast cell granules. Therefore, mast cells seem
to play a crucial role in airway remodeling by releasing
tryptase onto smooth muscle and epithelium, and may play
a role in skin tissue remodeling by releasing chymase in an
IgE-dependent manner in allergic diseases.
These data suggest multiple mechanisms and multiple
levels in different organs in the human body, where mast
cells can regulate tissue fibrosis and repair, and provide
evidence for the direct involvement of mast cells in fibrosis
and human connective tissue remodeling.Conclusions
Mast cells are fascinating, multifunctional, bone marrow-
derived, tissue-dwelling cells. They can be activated to
degranulate in minutes, not only by IgE and antigen signaling
via the high-affinity receptor for IgE, but also by a diverse
group of stimuli. These cells can release a wide variety of
immune mediators, including an expanding list of cytokines,
chemokines, and growth factors. Mast cells have been shown
to play roles in allergic inflammation and, more recently,
they have been shown to modulate coagulation cascades,
host defense, and tissue remodeling. The role ofmast cells in
asthma and other diseases is being actively studied.
This review suggests that mast cells may not only
contribute to the chronic airway inflammatory response,
airway remodeling and symptomatology, but may also have
acentral roleat the initiationof theallergic immuneresponse,
that is, providing signals inducing B cell IgE synthesis and Th2
lymphocyte differentiation. Th-targeted therapy would be of
considerable interest in controlling allergic asthma. Havingmore knowledge and resources about mast cells can lead to
finding cures to diseases caused by the mast cells.
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